Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

MDM2

4 articles · Resources: NCBI Gene, OncoKB

Clinical · Molecular biology

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer

Cowzer D, Walch H, Atri P, et al.

Clinical cancer research

This study analyzed a cohort of 1,254 patients with biliary tract cancer to assess the utility of targeted NGS molecular profiling. It revealed that 59% of patients harbored at least one OncoKB alteration, and 32.2% had level 1/2 alterations, with varying frequencies across tumor locations. Targeted therapies were associated with improved progression-free survival but not overall survival. The study also identified co-occurring alterations and acquired resistance mechanisms, such as ERBB2 loss or alterations in the RAS, MEK, MET, MYC, and CDKN2A pathways. These findings highlight genomic heterogeneity and the importance of precision medicine in informing future drug development efforts.

Clinical · Molecular biology

Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer after Progression on First-line Osimertinib: Phase II ORCHARD Study

Yu HA, Tang KH, Markovets A, et al.

Clinical cancer research

The Phase II ORCHARD study investigated resistance mechanisms to first-line osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Utilizing next-generation sequencing (NGS) on both tissue and plasma samples, the study characterized the molecular profile of tumors after progression. Resistance alterations were detected in 87% of samples, often multiple, involving genes such as TP53, MDM2/4, PI3K, SOX2, and MYC. These findings highlight the heterogeneity of resistance and provide a rationale for exploring combination therapies to improve patient outcomes.

Clinical · Molecular biology

Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study

Hartley HE, Fong FC, Gabriel AS, et al.

JCO precision oncology

This international study aimed to identify genetic prognostic biomarkers in a specific subgroup of intermediate-risk neuroblastoma patients, over 18 months old, without MYCN amplification, with localized unresectable or stage 3 tumors, and unfavorable histology, who experience poorer outcomes. Researchers analyzed chromosomal copy number alterations, next-generation DNA sequencing, telomere maintenance mechanisms, and gene expression. The findings revealed that oncogene amplifications, p53 pathway alterations, and typical segmental chromosomal aberrations (tSCAs) are independent prognostic markers associated with significantly reduced event-free and overall survival. These discoveries suggest that these patients might benefit from intensified or alternative treatments.

Clinical · Molecular biology

Gastric-Type Adenomas of the Nonampullary Duodenum: Reappraisal of Clinicopathological and Molecular Features and a Proposal for Novel Classification

Yamamoto H, Kawatoko S, Oshiro Y, et al.

The American journal of surgical pathology

This study re-evaluates the clinicopathological and molecular features of nonampullary duodenal neoplasms with gastric phenotype, proposing a novel classification. Analyzing 105 lesions, researchers observed a predominance of low-grade tumors and frequent heterogeneity. Next-generation sequencing revealed recurrent mutations in GNAS, KRAS, and APC. MDM2 gene amplification was identified as a potential marker for histological progression in high-grade tumors. Despite morphological diversity, the prognosis was extremely favorable, with no metastases, supporting the reclassification as "gastric-type adenomas."